ICH E6(R3) in Effect: Transforming Quality Management for Cell and Gene Therapy Trials
October 8, 2025
By MasterControl
ICH E6(R3) is here, and it's game-changing for cell and gene therapy developers. With only 5%-10% of needed manufacturing capacity available, this principle-based guidance emphasizes risk management and digital tools that align perfectly with modern CGT operations. Companies implementing these approaches are seeing 75%-80% faster batch releases and 90% fewer errors. Find out why that changes everything.
Full story